InflaRx N.V. Price & Performance (IFRX)

Short interest in InflaRx (NASDAQ: IFRX) surged by 46.2% in February, reaching 564,700 shares as of February 28. This increase reflects growing bearish sentiment despite the company’s recent advancements in its clinical pipeline. The short-interest ratio now stands at 1.5 days, based on average daily trading volume.12

InflaRx has successfully raised $30 million through a public offering of shares and pre-funded warrants. The funds are earmarked for advancing its clinical programs, including vilobelimab and INF904. This capital injection provides critical resources for the company’s ongoing development efforts in the competitive anti-inflammatory therapeutics market.34

At the 2025 AAD Annual Meeting, InflaRx presented positive data on vilobelimab for treating pyoderma gangrenosum and hidradenitis suppurativa. The drug demonstrated significant reductions in C5a levels and was well-tolerated across all doses, underscoring its potential as a treatment for these challenging inflammatory conditions.56